[Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens]

MLA

H J, Fan, et al. “[Influence of Polymorphisms of VEGFR2 on Clinical Outcomes and Safety of Advanced Non-Small-Cell Lung Cancer Treated by First Line Bevacizumab plus Chemotherapy Regimens].” Zhonghua Yi Xue Za Zhi, vol. 99, no. 2, Jan. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........c5867a9149af6467477ddb4d50a6b144&authtype=sso&custid=ns315887.

APA

H J, F., J, Y., J J, W., Y X, J., Y H, M., & X Y, L. (2019). [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens]. Zhonghua Yi Xue Za Zhi, 99(2).

Chicago

H J, Fan, Yuan J, Wu J J, Jia Y X, Ma Y H, and Li X Y. 2019. “[Influence of Polymorphisms of VEGFR2 on Clinical Outcomes and Safety of Advanced Non-Small-Cell Lung Cancer Treated by First Line Bevacizumab plus Chemotherapy Regimens].” Zhonghua Yi Xue Za Zhi 99 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........c5867a9149af6467477ddb4d50a6b144&authtype=sso&custid=ns315887.